Chau Khuong

OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada.

Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO.

Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA.

Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

Marika, Inc. is a development stage company which provides online job marketplace that connects people or companies in need to run errands or small tasks and the persons who wish to assist in running those errands or small tasks. Its services include: payment of utility bills, locating quality entertainment, picking up dry cleaning, grocery shopping, returning library books/videos, taking the car to the mechanic, party and event planning and all the other routine tasks. The company plan to conduct operations and market its services primary to North American and European markets. The company was founded on May 24, 2013 and is headquartered in Henderson, NV.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany.

Veritas Medicine, Inc. operates an online database of clinical trials. It offers patient enrollment solutions to determine eligibility for upcoming clinical trials. The company was founded by Robert Adelman, Joshua Schultz, and Stephen Knight in 1999 and is headquartered in Cambridge, MA.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON.

Arius, Inc. manufactures electrical testing equipment. The company was founded in 1999 and is headquartered in Frederick, MD.

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA.

ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom.

Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada.

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.

Perfuse Therapeutics, Inc. operates as biotechnology company that focuses on retinal perfusion. The company was founded by Sevgi Gurkan in 2018 and is headquartered in San Francisco,CA.

Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York.

Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021.

OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then.

Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL.